InterVenn Biosciences Joins the WIN and FNIH Biomarker Consortiums to Introduce a Glycoproteomic Option for Liquid Biopsies

Networks will be instrumental in reaching patients and caregivers, making them aware of our platform and realizing its potential

InterVenn Biosciences Announces New Data Validating the Clinical Performance of DAWN™ IO Melanoma as a Novel Liquid Biopsy Test to Improve Assessment of Benefit to Cancer Patients

DAWN™ IO Melanoma is commercially available as a unique glycoproteomics laboratory-developed test (LDT) that aids Oncologists in planning treatment for Melanoma